Skip to main content
. 2022 Nov 8;10:1002466. doi: 10.3389/fpubh.2022.1002466

Table 1.

Socio-demographic and clinical characteristics of the study population (N = 971).

Variable N (%)
Age (years)
<50 172 (17.7%)
50–60 397 (40.9%)
>60 402 (41.4%)
Gender
Male 452 (46.5%)
Female 519 (53.5%)
BMI (kg/m 2 )
Normal: <25 72 (7.4%)
Overweight: 25–29.9 297 (30.6%)
Obese: ≥30 602 (62.0%)
Waist circumference (cm)
(M < 94, F < 80) 88 (9.1%)
(M ≥ 94, F ≥ 80) 883 (90.9%)
Marital status
Married 826 (85.1%)
Single 32 (3.3%)
Divorced/ widow 113 (11.6%)
Occupational status
Employed 236 (24.3%)
Not employed 735 (75.7%)
Monthly income (JD)
< 300 294 (30.3%)
301–500 344 (35.4%)
>500 333 (34.3%)
Diabetes duration (years)
>10 462 (47.6%)
≤ 10 509 (52.4%)
Diabetes treatment
Oral Hypoglycemic agents (OHA) 501 (51.6)
Insulin only 30 (3.1%)
Insulin + OHA 440 (45.3%)
Statin duration (years)
>5 420 (53.5%)
≤ 5 365(46.5%)
Smoking
Yes 266 (27.4%)
No 705 (72.6 %)
Level of education
High school or less 453 (46.7%)
More than high school 518 (53.3%)
Received anti-dyslipidemia agent 882 (84.7%)
Statins 782 (80.5%)
Fibrates 104 (10.7%)
Statin-fibrate combination 92 (9.5%)
Ezetimibe 2 (0.2%)
Omega-3 172 (17.7%)
Comorbidities
Hypertension 662 (68.2%)
Ischemic heart disease 182 (18.7%)
Hypothyroidism 127 (13.1%)
At least one comorbidity 729 (75.1%)
Diabetes complications
Retinopathy 234 (24.1%)
Neuropathy 266 (27.4%)
Nephropathy 147 (15.1%)
At least one complication 458 (47.2%)